14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $141.16 $183.01 Friday, 3rd May 2024 AFMD stock ended at $5.42. This is 2.26% more than the trading day before Thursday, 2nd May 2024. During the day the stock fluctuated 8.04% from a day low at $5.10 to a day high of $5.51.
90 days $141.16 $227.30
52 weeks $84.73 $227.30

Historical Affimed N.V. prices

Date Open High Low Close Volume
Jun 18, 2020 $34.30 $36.74 $34.00 $35.70 101 803
Jun 17, 2020 $36.30 $37.50 $34.40 $34.80 110 630
Jun 16, 2020 $34.30 $35.60 $33.57 $35.50 151 775
Jun 15, 2020 $29.90 $33.55 $29.30 $32.80 509 745
Jun 12, 2020 $31.10 $31.70 $29.00 $30.60 545 208
Jun 11, 2020 $30.30 $31.90 $29.80 $30.00 107 113
Jun 10, 2020 $33.20 $33.80 $32.10 $32.40 71 603
Jun 09, 2020 $33.50 $34.20 $33.00 $33.10 59 775
Jun 08, 2020 $36.00 $36.00 $33.24 $33.90 83 150
Jun 05, 2020 $33.50 $36.00 $32.70 $34.80 142 269
Jun 04, 2020 $34.60 $36.60 $32.50 $33.10 126 342
Jun 03, 2020 $34.70 $36.60 $33.20 $34.10 148 814
Jun 02, 2020 $32.70 $34.80 $31.90 $34.50 128 267
Jun 01, 2020 $32.60 $34.00 $32.50 $32.50 67 086
May 29, 2020 $30.30 $33.40 $29.70 $32.90 127 001
May 28, 2020 $31.70 $33.90 $30.80 $31.20 137 986
May 27, 2020 $31.40 $32.25 $30.30 $31.60 140 665
May 26, 2020 $31.20 $32.30 $29.50 $31.10 142 960
May 22, 2020 $28.70 $30.60 $28.10 $29.90 94 474
May 21, 2020 $28.80 $29.20 $27.30 $28.70 77 927
May 20, 2020 $29.60 $29.80 $27.70 $29.00 126 697
May 19, 2020 $24.70 $29.70 $24.50 $28.50 731 973
May 18, 2020 $24.40 $25.30 $23.70 $24.60 374 632
May 15, 2020 $20.90 $24.00 $20.00 $23.60 145 360
May 14, 2020 $20.50 $20.50 $18.80 $19.80 94 984
Click to get the best stock tips daily for free!

About Affimed N.V.

Affimed N.V. Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispec... AFMD Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT